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Introduction
Skeletal muscles comprise 40–50% of total body mass and con-
stitute the major protein reservoir of the organism. When muscle 
mass decreases in fasting and in many systemic diseases, amino 
acids from muscle proteins are mobilized to provide substrates 
for hepatic gluconeogenesis and for the synthesis of critical pro-
teins. The resulting loss of muscle mass in these catabolic states 
and upon denervation or disuse involves a common transcriptional 
program (Sandri et al., 2004, 2006; Stitt et al., 2004; Zhao et al., 
2007), resulting in a general acceleration of proteolysis and a   
decrease in protein synthesis in most catabolic states (Furuno   
et al., 1990; Medina et al., 1995; Wing et al., 1995; Mitch and 
Goldberg,  1996;  Jagoe  and  Goldberg,  2001;  Glass,  2005;   
Kandarian and Jackman, 2006). We have identified a set of 100 
atrophy-related genes or “atrogenes” whose expression increases 
and decreases similarly in various types of muscle atrophy (Lecker 
et al., 2004; Sacheck et al., 2007). Among the genes induced 
most dramatically during atrophy are two muscle-specific ubiqui-
tin ligases, atropin-1/MAFbx (muscle atrophy F-box) and MuRF-1 
(muscle RING finger-1; Lecker et al., 2004; Sacheck et al.,   
2007), whose induction is essential for rapid atrophy (Bodine   
et al., 2001a; Gomes et al., 2001; Jagoe et al., 2002). Activation 
of the FoxO transcription factors has been shown to be crucial 
in the development of muscle wasting and for the induction of 
atrogin-1 and MuRF-1 (Sandri et al., 2004; Stitt et al., 2004). 
Moreover, activation of FoxO3 by itself is sufficient to cause 
dramatic atrophy (Sandri et al., 2004).
In growing muscles, FoxOs are maintained in an inactive 
state by the IGF-1/phosphoinositide 3-kinase (PI3K)/Akt sig-
naling cascade (Sandri et al., 2004). This pathway plays a key 
role in the regulation of muscle mass (Bodine et al., 2001b; 
T
he size of skeletal muscle cells is precisely regu-
lated by intracellular signaling networks that deter-
mine the balance between overall rates of protein 
synthesis and degradation. Myofiber growth and protein 
synthesis  are  stimulated  by  the  IGF-1/Akt/mammalian 
target of rapamycin (mTOR) pathway. In this study, we 
show that the transcription factor JunB is also a major   
determinant of whether adult muscles grow or atrophy. 
We found that in atrophying myotubes, JunB is excluded 
from  the  nucleus  and  that  decreasing  JunB  expression 
by RNA interference in adult muscles causes atrophy.   
Furthermore,  JunB  overexpression  induces  hypertrophy 
without affecting satellite cell proliferation and stimulated 
protein synthesis independently of the Akt/mTOR path-
way. When JunB is transfected into denervated muscles, 
fiber atrophy is prevented. JunB blocks FoxO3 binding to 
atrogin-1 and MuRF-1 promoters and thus reduces pro-
tein breakdown. Therefore, JunB is important not only in 
dividing populations but also in adult muscle, where it 
is required for the maintenance of muscle size and can 
induce rapid hypertrophy and block atrophy.
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trigger atrophy might decrease JunB levels in the nucleus, we 
measured the amount of this protein in nuclear and cytosolic 
fractions of differentiated C2C12 myotubes treated with the 
glucocorticoid dexamethasone for 24 h or after removal of growth 
medium for 5 h (Fig. 1 A). These treatments induce protein loss 
and many of the biochemical features of muscle atrophy in adult 
animals (Bodine et al., 2001b; Gomes et al., 2001; Sacheck et al., 
2004; Sandri et al., 2004; Stitt et al., 2004). After both treat-
ments, the levels of JunB protein were dramatically reduced in 
the nucleus (Fig. 1 A), whereas no change was apparent in the 
cytosolic fraction (Fig. 1 A).
To  determine  the  physiological  consequences  of  this 
fall in nuclear JunB, we decreased the JunB content of adult 
mouse muscles using JunB RNAi, and we studied the effects of 
its inhibition on muscle mass. A vector expressing small hair-
pin RNAs (shRNAs) against JunB, which specifically blocked 
JunB expression in murine embryonic fibroblast cells (Fig. S3,   
A and B), was electroporated into tibialis anterior (TA) muscles. 
This technique allows high transfection efficiency of myofibers 
without causing significant damage or inflammation and has been 
very useful in clarifying regulatory mechanisms in muscle (Sandri 
et al., 2004, 2006; Mammucari et al., 2007; Sartori et al., 2009;   
Romanello et al., 2010). Moreover, with our electroporation   
protocol, only adult myofibers are transfected and not interstitial 
cells or satellite cells, the muscle stem cells (Figs. 1 B and S1, A–D).   
To knock down target proteins in vivo for days or weeks, we   
used bicistronic vectors that simultaneously encode for shRNAs 
and GFP. Therefore, detection of GFP fluorescence allows us to 
monitor the efficiency of transfection and the changes in size of 
myofibers containing shRNAs. Thus, we transfected adult TA 
muscles with vectors producing shRNAs specific for JunB or 
unrelated oligos (scramble). Dystrophin staining confirmed that 
we successfully transfected adult myofibers and not interstitial 
cells (Fig. 1 B). JunB levels dramatically fell in muscles that 
were transfected with specific oligos against JunB (Fig. 1 C).   
When expressed in vivo for 12 d, the shRNA caused a 20% reduc-
tion in the mean cross-sectional area (Fig. 1, D and E) below levels 
in control fibers electroporated with scramble shRNA. To examine 
the effect of a more prolonged reduction in JunB content, we   
transfected TA muscles with JunB RNAi and scramble as a   
control and collected the muscles 1 mo later. JunB knockdown 
for 1 mo resulted in a 25% reduction in myofiber size (Fig. 1 F). 
Thus, in normal adult muscle, JunB is required for the main-
tenance of muscle mass, and its down-regulation or nuclear ex-
clusion causes a prolonged loss of muscle mass.
JunB stimulates protein synthesis 
and hypertrophy of adult muscle fibers 
independently of Akt and mTOR
These RNAi-mediated decreases in muscle mass (Fig. 1, D–F) 
prompted us to investigate whether, conversely, JunB over-
expression can promote muscle growth. To learn whether JunB 
expression induces hypertrophy, we electroporated a plasmid 
encoding JunB into the TA muscles of adult mice. Dystrophin and 
Hoechst staining confirmed that JunB was expressed only in adult 
fibers and was correctly localized only in the myonuclei (Fig. 2 A). 
JunB overexpression for 9 d caused dramatic hypertrophy of the 
Rommel et al., 2001) and promotes fiber hypertrophy by stimu-
lating overall protein synthesis and suppressing proteolysis.   
In skeletal muscle, activation of Akt by IGF-1 stimulates protein 
translation through induction of mammalian target of rapamycin 
(mTOR), which activates p70S6K and inactivates the inhibitor 
of translational initiation 4EBP1 (Bodine et al., 2001b; Rommel 
et al., 2001), and GSK-3, which stimulates the initiation factor 
eIF2B. In addition, Akt suppresses muscle protein breakdown 
mainly by phosphorylating FoxO3, which leads to its inactiva-
tion through sequestration in the cytosol (Sandri et al., 2004; 
Stitt et al., 2004). In contrast, during atrophy, the activity of the 
IGF-1/PI3K/Akt pathway decreases, leading to the activation of 
FoxO3, which leads to a stimulation of protein breakdown not 
only by the ubiquitin–proteasome pathway (Sandri et al., 2004; 
Stitt et al., 2004) but also by the autophagic/lysosomal system 
(Mammucari et al., 2007; Zhao et al., 2007).
Although many transcription factors have been implicated 
in the differentiation of muscle and in muscle atrophy, none has 
been shown to promote growth of adult muscle. Here, we demon-
strate that the transcription factor JunB is sufficient to promote 
muscle growth independently of changes in the Akt pathway. 
JunB attracted our attention because we had found that its 
mRNA was markedly down-regulated in muscle during various 
types of atrophy, including denervation, disuse, fasting, diabetes, 
sepsis, acidosis, and cancer cachexia (Lecker et al., 2004;   
Sacheck et al., 2004). This transcription factor belongs to the 
activator protein-1 (AP-1) family, which includes both the Jun 
and also Fos families (Angel et al., 1987, 1988; Curran and 
Franza, 1988; Halazonetis et al., 1988; Hirai and Yaniv, 1989), and 
we had found that during starvation in myotubes, the DNA binding 
activity of nuclear extracts to the AP-1 binding sites decreases 
(Sandri et al., 2004). JunB and Fos belong to a class of immedi-
ate early genes that are rapidly activated, usually transiently, in 
response to cytokines, growth factors, stress signals, infection, 
or oncogenic stimuli (Sng et al., 2004). Every cell type contains 
a complex mixture of AP-1 dimers with subtly different func-
tions (Wagner, 2001), which respond to various physiological 
and pathological stimuli.
However, JunB function has been investigated primarily 
in dividing cell populations, and its role in skeletal muscle or 
other postmitotic tissues has been barely studied. Treatment of 
cardiac myocytes with insulin was found to stimulate the binding 
of the AP-1 transcription factor to its specific consensus se-
quence (Markou et al., 2008). This observation, together with 
the decrease of JunB expression during atrophy (Lecker et al., 
2004; Sacheck et al., 2007), suggested that an AP-1 factor might 
play an important role in the maintenance of muscle mass and 
that the decrease in its transcriptional activity might contribute 
to the loss of muscle mass in atrophic conditions.
Results
JunB is required for maintenance  
of muscle mass
We previously found that the DNA-binding activity of nuclear 
extracts to the AP-1 binding sites decreases during starvation in 
myotubes (Sandri et al., 2004). To learn whether conditions that 103 JunB and muscle hypertrophy • Raffaello et al.
transfected fibers (Fig. S2 B). Together, these findings, along with 
the lack of effect of JunB on basal protein degradation (see the 
next paragraph), indicate that JunB induces hypertrophy of normal 
muscles by stimulating protein synthesis.
Surprisingly, this stimulation of protein synthesis in the 
myotubes occurred independently of any clear activation (i.e., 
phosphorylation) of components of the PI3K/Akt/mTOR path-
way (Fig. 3 B), in sharp contrast to the stimulation of synthesis   
by IGF-1 or insulin (Bodine et al., 2001b; Rommel et al., 2001). 
Specifically, we did not observe increases in either the total 
level or the phosphorylated forms of the key components of 
this pathway (e.g., Akt or S6K) that are generally believed to be   
crucial for muscle hypertrophy (Bodine et al., 2001b; Rommel 
et al., 2001). On the contrary, JunB overexpression actually 
decreased the levels of phosphorylated Akt, S6K, and 4EBP1 
without affecting the amount of the TORC1 proteins mTOR and 
raptor (Fig. 3 B). Furthermore, when a similar analysis was per-
formed on components of the PI3K/Akt pathway in TA mouse 
muscles during hypertrophy induced by JunB electroporation 
for 9 d, there was no evidence of activation of this pathway, as 
was found in myotubes (Fig. S3 C).
transfected fibers (Fig. 2, B and C). The mean cross-sectional 
area of these fibers was 40% greater than that of neighboring 
nontransfected fibers within the same muscle or fibers trans-
fected with mock plasmid (Fig. 2, B and C). In contrast, trans-
fection of another AP-1 family member, c-Jun, did not affect 
myofiber size (Fig. 2 B), indicating that the capacity to increase 
muscle mass is a specific action of JunB.
Hypertrophy of a cell occurs when its overall rate of protein 
synthesis exceeds the overall rate of protein degradation. To test 
whether JunB induced growth by increasing protein synthesis, we 
measured rates of synthesis in myotubes infected with adenoviruses 
expressing either JunB or GFP (mock plasmid; Fig. 3 A). Within 
12 h of infection, JunB enhanced [
3H]tyrosine incorporation into 
protein by 50%, and this effect was then maintained for the course 
of the experiment. These findings make it likely that the rapid 
hypertrophy induced by JunB in adult fibers is a result of enhanced 
protein synthesis. To confirm the importance of increased synthesis 
in vivo (Fig. 2, B and C), TA muscles were electroporated with the 
JunB expression vector, and, 4 d later, animals were treated with 
cycloheximide as described in Fan et al. (2010) to inhibit protein 
synthesis. Cycloheximide significantly decreased the growth of the 
Figure 1.  JunB is decreased in the nuclei of atrophying myotubes, and its down-regulation in adult muscles induces muscle atrophy. (A) JunB protein levels 
in C2C12 myotubes either untreated, starved, or by treatment with dexamethasone. Nuclear and cytosolic fractions were immunoblotted for JunB, nuclear 
(HDAC1), and cytoplasmic (-tubulin) proteins. (B–F) The down-regulation of JunB expression induces atrophy. Adult skeletal muscles were transfected with 
vectors expressing shRNA against JunB or scramble for 12 d. (B) Cryosections were stained for dystrophin to identify plasma membrane (sarcolemma) of 
myofibers and counterstained with Hoechst. Images were merged to demonstrate that the GFP signal lay under the sarcolemma and not in interstitial cells.   
(C) JunB mRNA levels measured after transfection of TA muscles with scramble oligos or specific shRNA against JunB. n = 4; means ± SD. (D) Mean cross- 
sectional areas of 500 fibers expressing the control siRNA (scramble) and fibers expressing shRNA against JunB for 12 d ± SEM. n = 4. (C and D) *, P < 0.005.   
(E) Frequency histograms of the cross-sectional area of fibers with JunB knockdown (open bars) compared with fibers expressing control scramble oligos 
(shaded bars). n = 4. The numeric data are expressed as the mean fiber sizes ± SEM. (F) The bar diagram represents the mean cross-sectional areas of fibers 
expressing the control siRNA (scramble) and fibers expressing shRNA against JunB for 1 mo. The experiment was performed as in D. *, P < 0.01.JCB • VOLUME 191 • NUMBER 1 • 2010   104
Because contractile proteins comprise >40% of total muscle   
proteins, we tested whether JunB, while stimulating muscle hyper-
trophy, affects myosin gene expression. We cotransfected JunB 
and a promoter reporter construct for fast (myosin heavy chain 
type 2B [MyHC-2B]) myosin into the glycolytic fast TA muscle. 
JunB greatly enhanced transcription of the MyHC-2B promoter   
(Fig. 3 E). This finding is noteworthy because MyHC-2B is the most 
abundant myosin in TA muscles and is induced during fiber hyper-
trophy. Furthermore, we observed a similar increase in MyHC-2B 
mRNA in myotubes overexpressing JunB by adenovirus infection 
(Fig.  3  F).  In  addition,  chromatin  immunoprecipitation  (ChIP) 
analysis confirmed the binding of JunB to the MyHC-2B promoter 
(Fig. 3 G). Thus, JunB promotes hypertrophy by enhancing overall 
protein synthesis and by activating myosin expression.
JunB blocks muscle atrophy and inhibits 
atrogin-1 and MuRF-1 induction
Because of JunB’s ability to enhance protein synthesis and to 
promote growth of adult muscles in vivo, we tested whether 
JunB could inhibit denervation atrophy of mouse muscles. The 
sciatic nerve in adult mice was cut to induce rapid atrophy of   
the TA muscle, and, at the same time, a JunB expression vector 
was transfected into the muscle. 9 d later, the denervated, un-
transfected  fibers  decreased  in  mean  cross-sectional  area  by 
30% compared with fibers in the controlateral innervated muscle 
(Fig. 4, B and C). However, overexpression of JunB in the de-
nervated fibers (Fig. 4 A) completely prevented this decrease in 
the cross-sectional area (Fig. 4, B and C).
Because this apparent enhancement of synthesis without   
activation of mTOR was surprising, we further tested these conclu-
sions by blocking mTORC1 activity with rapamycin treatment in 
myotubes overexpressing JunB or GFP (mock plasmid; Fig. 3 C). 
Rapamycin reduced [
3H]tyrosine incorporation into protein in con-
trol myotubes by 29%, but JunB overexpression maintained pro-
tein synthesis at control levels despite the presence of rapamycin 
(Fig. 3 C). To our knowledge, these findings represent the first   
example of a stimulation of overall protein synthesis and hyper-
trophy of muscle that is independent of Akt or mTOR.
To confirm this conclusion in vivo, we transfected JunB 
into adult muscle of transgenic mice expressing tamoxifen- 
inducible Akt specifically in skeletal muscle (Mammucari et al., 
2007). As expected, activation of Akt expression in muscle induced   
hypertrophy, but the overexpression of JunB further increased the   
mean myofiber cross-sectional area by 50% (Fig. 3 D). Together, 
these findings show that the stimulation of synthesis by JunB 
and Akt is independent and additive.
In addition, we tested whether JunB-mediated hypertrophy 
involves the activation and fusion of satellite cells, the muscle 
stem cells. To test this possibility, we treated mice with BrdU after 
transfection. 9 d later, we monitored for incorporation of BrdU-
positive nuclei into fibers expressing JunB. However, we never 
detected BrdU in myonuclei of transfected fibers (Fig. S2 A, 
left). In control experiments, we could confirm efficient incorpo-
ration of BrdU into myonuclei in damaged muscles undergoing 
regeneration (Fig. S2 A, right). Thus, JunB-mediated hypertrophy   
does not require activation and recruitment of satellite cells.   
Figure 2.  JunB stimulates the growth of fibers in TA muscles. TA muscles of adult mice were electroporated with JunB and were analyzed 9 d later.   
(A) Localization of JunB and dystrophin. Images were merged to demonstrate that the JunB-positive nuclei lay under the sarcolemma. The arrows indicate the 
myonuclei overexpressing JunB. (B) JunB, but not c-Jun, causes myotube hypertrophy. Mean cross-sectional area of transfected fibers overexpressing either 
JunB or c-Jun for 9 d compared with the area of the surrounding untransfected myofibers (control). For each condition, at least 500 fibers were counted,   
n = 4. Values are means ± SEM. *, P < 0.001. (C) Frequency histograms showing the distribution of cross-sectional areas of 500 fibers expressing JunB 
for 9 d (open bars) and an equal number of surrounding nontransfected fibers (control fibers; shaded bars). The numeric data are expressed as the mean 
fiber areas ± SEM, n = 4.105 JunB and muscle hypertrophy • Raffaello et al.
(ca-FoxO3) in myotubes causes dramatic fiber atrophy (Sandri 
et al., 2004; Zhao et al., 2007). However, JunB overexpression 
(Fig. 4 F) together with ca-FoxO3 completely prevented the FoxO-
mediated atrophy (Figs. 4, F and G and S4 B).
To clarify the mechanisms for this dramatic prevention   
of atrophy, we investigated whether JunB overexpression in   
atrophying muscles and myotubes affects the induction of the 
critical atrophy-linked ubiquitin ligases atrogin-1 and MuRF-1 
A similar inhibition of atrophy was observed in myotubes 
under  catabolic  conditions.  Both  nutrient  removal  and  dexa-
methasone treatment caused myotube atrophy (Fig. 4 D; Sandri 
et al., 2004), and JunB overexpression completely prevented 
these decreases of myotube size (Fig. 4, D and E). Because cata-
bolic stimuli activate FoxO transcription factors, we also used a 
genetic approach to activate the atrophy program in myotubes.   
It is known that the overexpression of constitutively active FoxO3 
Figure 3.  JunB promotes rapid muscle fiber growth by increasing protein synthesis independently of the Akt/mTOR pathway. (A) JunB enhances protein 
synthesis in differentiated myotubes. At different times after infection with adenoviruses expressing JunB or GFP (mock plasmid), cells were incubated with 
[
3H]tyrosine for 2 h. The radioactivity incorporated, normalized to total protein, was determined. (B) The effects of JunB and ca-FoxO3 on phosphorylation 
of components of the AKT pathway are depicted. Differentiated myotubes were infected for 12 and 24 h with either mock (GFP), JunB, or ca-FoxO3 adeno-
virus. Immunoblot analysis with specific antibodies was performed. (C) JunB stimulates protein synthesis in differentiated myotubes even in the presence of 
rapamycin. C2C12 myotubes were infected with control GFP- or JunB-expressing adenoviruses with or without rapamycin. The experiment was performed 
as in A. (A and C) n = 6; means ± SD. *, P < 0.01. (D) Overexpression of JunB in TA muscles of Akt transgenic mice stimulates further hypertrophy. Adult 
muscles of transgenic animals expressing activated Akt under control of tamoxifen (Mammucari et al., 2007) were transfected with a plasmid expressing 
JunB for 9 d. Akt was activated by tamoxifen injection immediately after electroporation. The bar diagram represents the mean cross-sectional area of at 
least 500 control fibers expressing Akt and of the same number of fibers coexpressing JunB ± SEM. n = 3. *, P < 0.01. (E) Effect of JunB on the activity of 
the myosin heavy chain type 2B (MyHC-2B) promoter. Mouse TA muscles were electroporated with MyHC-2B promoter, driving the firefly luciferase gene 
and the control vector pRL-TK with or without JunB for 9 d. The values represent the firefly activity normalized to renilla luciferase activity. n = 3; means ± SD.   
*, P < 0.01. (F) Effect of the overexpression of JunB on MyHC-2B mRNA. C2C12 myotubes were infected with either JunB or GFP adenoviruses. At different 
time points, cells were collected, and total RNA was analyzed by quantitative RT-PCR. n = 3; means ± SD. *, P < 0.005. (G) JunB induces the expression 
of MyHC-2B by direct binding to its promoter. Differentiated myotubes were infected with either mock (GFP) or JunB adenoviruses. After 48 h, ChIP was 
performed using anti-JunB and anti-acetyl histone antibodies. A set of primers that cover the JunB response elements of the MyHC-2B promoter was used to 
amplify by PCR the related DNA fragments on the MyHC-2B promoter as depicted in the top panel.JCB • VOLUME 191 • NUMBER 1 • 2010   106
data, overexpression of JunB in myotubes (Fig. S4 A) completely 
blocked atrogin-1 induction (Fig. 5 C) and partially inhibited 
that of MuRF-1 (Fig. 5 D) during dexamethasone treatment and 
nutrient deprivation, both of which induce myotube atrophy   
and induction of atrogin-1 and MuRF-1 (Sandri et al., 2004).   
using promoter reporter constructs (Bodine et al., 2001a; Gomes 
et al., 2001; Lecker et al., 2004; Sacheck et al., 2007). Impor-
tantly, JunB overexpression in the denervated muscles prevented 
the activation of the atrogin-1 promoter (Fig. 5 A) and greatly 
reduced that of MuRF-1 (Fig. 5 B). Consistent with the in vivo 
Figure 4.  JunB blocks fiber atrophy induced 
by  denervation  of  TA  muscles  and  myotube 
atrophy induced by ca-FoxO3, treatment with 
dexamethasone,  and  starvation.  (A–C)  JunB 
counteracts  the  decrease  in  fiber  size  upon 
denervation.  JunB  was  electroporated  into 
TA muscles of adult mice, and, at the same 
time, the left hindlimb was denervated. 9 d 
after denervation, the TA muscles were ana-
lyzed by immunohistochemistry. (A) JunB and 
dystrophin  staining  demonstrates  that  JunB-
positive nuclei lay under the sarcolemma. The 
arrows  indicate  the  myonuclei  overexpress-
ing JunB. (B) Cross-sectional area of at least 
500 transfected fibers identified by anti-JunB 
immunofluorescence was measured as previ-
ously described and compared with an equal 
number  of  untransfected  denervated  fibers 
and control innervated fibers ± SEM. n = 4. 
*, P < 0.001. (C) Frequency histograms show-
ing the distribution of cross-sectional areas of 
500 denervated fibers (light blue bars), of 
500 denervated fibers expressing JunB for   
9 d (open bars), and an equal number of inner-
vated fibers (control fibers; shaded bars). The 
numeric data are expressed as the mean fiber 
sizes ± SEM. n = 4. (D and E) JunB increases 
the size of differentiated myotubes and blocks 
myotube atrophy induced by dexamethasone 
and  starvation.  5-d  differentiated  myotubes 
were  infected  with  adenoviruses  expressing 
mock  (GFP)  and  JunB.  (D)  The  panels  show 
the myotubes 48 h after infection. The myo-
tubes expressing control GFP and JunB were 
then treated with dexamethasone or starved.   
(E) The bar diagram represents the mean diam-
eter of at least 1,000 myotubes infected with 
mock  (GFP)  or  JunB  adenoviruses  untreated 
or treated with dexamethasone or starved ± 
SEM. n = 3. *, P < 0.001. (F and G) JunB 
increases the size of differentiated myotubes 
and counteracts FoxO3-induced atrophy. 5-d   
differentiated  myotubes  were  infected  with 
adenoviruses  expressing  mock  (GFP),  JunB,   
ca-FoxO3, and ca-FoxO3 together with JunB. 
(F) The panels show the myotubes 48 h after 
infection.  (G)  Mean  diameter  of  myotubes 
infected  with  mock  (GFP),  JunB,  ca-FoxO3,   
and  JunB  together  with  ca-FoxO3  adeno-
viruses. The experiment was performed as in E.   
*, P < 0.001. Means ± SEM.107 JunB and muscle hypertrophy • Raffaello et al.
also inhibit this stimulation of overall protein degradation by 
FoxO3. After labeling the bulk of cell proteins in myotubes with 
[
3H]tyrosine for 20 h (Zhao et al., 2007), the rate of degradation 
of long-lived proteins was measured in C2C12 myotubes after 
infection with adenoviruses bearing the JunB, FoxO3, or a mock   
(GFP) construct. As shown previously (Zhao et al., 2007),   
ca-FoxO3 expression stimulated overall proteolysis in myotubes 
above rates in control myotubes (Fig. 5 E). Overexpression of 
JunB alone did not change the basal rate of protein degrada-
tion, which supports our earlier conclusion that JunB stimulates 
growth of normal fibers (Fig. 2, B and C) by stimulating protein 
synthesis (Figs. 3 A and S2 B). However, JunB partially inhib-
ited the rise in proteolysis caused by ca-FoxO3 (Fig. 5 E). These 
findings are in accord with our finding that JunB suppresses the 
Quantitative RT-PCR confirmed that JunB overproduction mark-
edly decreased the levels of mRNA for these two ligases in un-
treated myotubes (Fig. S5, A and B). Thus, maintenance of high 
levels of JunB in catabolic conditions preserves muscle mass 
and blocks the atrophy program.
JunB inhibits the activation of proteolysis 
by FoxO3
The FoxO family of transcription factors plays a critical role 
in muscle atrophy upon denervation, and FoxO3 activation by 
itself can induce rapid atrophy as well as atrogin-1 and MuRF-1 
expression (Sandri et al., 2004) and stimulate proteasomal and 
autophagic/lysosomal  proteolysis  (Mammucari  et  al.,  2007; 
Zhao et al., 2007). We therefore tested whether JunB could 
Figure 5.  JunB greatly reduces the induction 
of the critical atrophy-related ubiquitin ligases 
atrogin-1 and MuRF-1 in TA muscles and in 
myotubes in atrophying conditions and reduces 
the increase in overall proteolysis induced by 
ca-FoxO3. (A and B) JunB overexpression in 
TA muscles blocks the induction of atrogin-1 
(A) and inhibits the induction of MuRF-1 (B) 
after denervation. Muscles were cotransfected 
with atrogin-1 or MuRF-1 promoter with pRL-TK   
in the presence or absence of JunB. After 6 d,   
the  muscles  were  denervated  unilaterally  by 
cutting the sciatic nerve to induce the expres-
sion of these two ubiquitin ligases. 2 d later, 
the  muscles  were  collected,  and  the  firefly/
renilla  luciferase  ratio  was  determined  as 
described in Fig. 3 E. n = 4; means ± SD.   
(C and D) Overproduction of JunB inhibits the 
induction of atrogin-1 (C) and MuRF-1 (D) pro-
moters in C2C12 myotubes starved or treated 
with dexamethasone. C2C12 myoblasts were 
transfected with atrogin-1 (Sandri et al., 2004) 
or  with  MuRF-1  promoters  with  or  without 
JunB.  A  renilla  luciferase  construct  (pRL-TK) 
was cotransfected to normalize for transfection   
efficiency.  5-d  differentiated  myotubes  were 
starved or incubated with dexamethasone as 
in Fig. 1 A. The expression of atrogin-1 and 
MuRF-1 promoters was determined by firefly 
activity and normalized for the renilla. n = 3;   
means  ±  SD.  (A–D)  *,  P  <  0.01.  (E)  JunB 
reduces  the  increase  in  overall  proteolysis 
induced  by  FoxO3.  To  label  cell  proteins, 
differentiated  myotubes  were  incubated  with 
[
3H]tyrosine for 20 h as described previously 
(Zhao et al., 2007). Cells were then infected 
with mock (GFP), ca-FoxO3, or JunB adeno-
viruses.  Media  samples  were  collected  over   
48 h. Proteolysis was measured as described 
previously (Zhao et al., 2007). n = 6; means ± SD.   
(F–I)  JunB  does  not  affect  autophagosome   
formation induced by starvation and ca-FoxO3. 
(F) Adult TA muscles were transfected with a 
plasmid  expressing  YFP-LC3  with  or  without 
JunB.  9  d  later,  mice  were  fasted  for  24  h 
before  sacrifice.  Myofibers  expressing  YFP-
LC3  were  analyzed  by  fluorescence  micros-
copy, and cryosections were stained for JunB.   
Autophagosomes were quantified as described 
previously (Mammucari et al., 2007). (G) Differentiated myotubes were infected with mock (GFP) or JunB adenoviruses for 48 h and then starved and 
treated with bafilomycin A for 5 h to inhibit lysosomes. Proteins were extracted, and LC3 lipidation was determined by the extent of conversion of LC3I to 
LC3II. (H) Adult TA muscles were transfected with a plasmid expressing YFP-LC3 with or without JunB and ca-FoxO3. 9 d later, mice were sacrificed, and 
autophagosomes were analyzed as in F. (F and H) n = 4; means ± SEM. *, P < 0.001. (I) Differentiated myotubes were infected with either mock (GFP), 
JunB, ca-FoxO3, or JunB with ca-FoxO3 adenoviruses for 48 h. Proteins were extracted and analyzed as in G. The HA line represents ca-FoxO3 expression 
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this inhibition of FoxO actions could be the result of a direct   
interaction of JunB with FoxO3, we performed a coimmuno-
precipitation experiment in myotubes infected with the control 
plasmid (GFP), JunB, ca-FoxO3, or both JunB and ca-FoxO3. This 
experiment clearly demonstrated that JunB forms a complex with 
FoxO3 (Fig. 6 C, top). The JunB–FoxO3 interaction was also con-
firmed by immunoprecipitating the endogenous proteins (Fig. 6 C, 
bottom). Together, these results indicate that JunB associates 
with FoxO3 to directly block its recruitment to the atrogin-1 and 
MuRF-1 promoters and thus inhibits muscle atrophy.
Because JunB induction of hypertrophy is independent of 
Akt signaling, we monitored whether JunB might influence the 
myostatin pathway. In fact, we have recently shown that myostatin 
inhibition induces hypertrophy in adult myofibers (Sartori et al., 
2009). Interestingly, JunB overexpression greatly suppressed myo-
statin expression in transfected myotubes (Fig. 6 D). Because a 
prior study has shown that JunB is downstream of TGF-/small   
mother against decapentaplegic (Smad) signaling (Li et al., 1990), 
we also monitored whether myostatin treatment could mod-
ulate JunB expression. However, at two different concentra-
tions tested, myostatin was unable to change the level of JunB 
transcript (Fig. 6 E). To further confirm that JunB can block 
myostatin  signaling,  we  monitored  Smad3  phosphorylation, 
the transcription factor downstream of myostatin. FoxO1 has, 
in fact, been shown to control myostatin expression (Allen and 
Unterman, 2007). Indeed, FoxO3 expression induced Smad3 
phosphorylation (Fig. 6 F). Conversely, JunB overexpression 
caused dephosphorylation of Smad3, confirming the inhibitory 
effect on myostatin expression (Fig. 6 F), and this effect prob-
ably contributes to the muscle growth induced by JunB.
Discussion
Although  it  is  well  established  that  JunB  is  of  fundamental 
importance in regulating cell proliferation (Bakiri et al., 2000; 
Passegué and Wagner, 2000), including proliferation of muscle 
cell progenitors (Chalaux et al., 1998), and also appears to sup-
press growth of certain tumors, few studies have addressed the 
role of JunB or other AP-1 family members in postmitotic cells. 
Our findings show that JunB, but not c-Jun, is a potent regulator 
of muscle mass in adult animals. Several studies have suggested 
that the activity of the AP-1 family is finely regulated in skel-
etal and cardiac muscles. For example, the expression of some of 
the members of this family, including JunB, can be induced by 
exercise (Trenerry et al., 2007) or insulin (Coletta et al., 2008), 
and JunB mRNA rises during cardiac hypertrophy induced by 
increased workload (Black et al., 1991),  agonists (Brand et al., 
1992), and electrical stimulation (Xia et al., 1997). These obser-
vations are consistent with our findings that JunB expression falls   
during various types of atrophy (Lecker et al., 2004; Sacheck   
et al., 2007), that JunB is excluded from the nucleus in atrophying 
myotubes (Fig. 1 A), and that the AP-1 binding to DNA sharply 
decreases during starvation of myotubes (Sandri et al., 2004). 
Furthermore, we found that the endogenous expression of JunB 
in normal muscles is required for the maintenance of muscle mass 
in adult animals. In fact, the decrease of JunB content (Fig. 1 C)   
leads to rapid decreases in fiber diameter (Fig. 1, D and E).   
activation of the atrogin-1 and MuRF-1 promoters (a FoxO3-
mediated effect) in atrophying muscles (Fig. 5, A and B).
Because the induction of protein breakdown by ca-FoxO3 
was only partially reduced, we monitored whether JunB also 
prevents the activation of the autophagic/lysosomal pathway by 
ca-FoxO3 or by fasting. Adult skeletal muscles were transfected 
with a YFP-LC3 plasmid to monitor autophagosome formation. 
Overexpression of JunB in vivo did not prevent autophagic vesicle 
formation in FoxO3-transfected TA or TA of fasted mice, as re-
vealed by the number of LC3-positive punctae (Fig. 5, F and H). 
Consistently, JunB overexpression also did not block the LC3 
lipidation during starvation or FoxO3 overexpression (Fig. 5,   
G and I). We have shown that FoxO3 activates autophagy by 
regulating the expression of several autophagy-related genes, 
including Bnip3 and Beclin-1 (Mammucari et al., 2007; Zhao 
et al., 2007), and the induction of Bnip3 and Beclin-1 is suffi-
cient for induced autophagosome formation (Mammucari et al., 
2007). Interestingly, JunB did not prevent the FoxO3-mediated 
induction of these two genes (Fig. S5 C). Thus, JunB does not 
decrease basal protein breakdown in muscle but can specifically 
reduce the stimulation of proteasomal-dependent protein degra-
dation by FoxO3 (Fig. 5 E). This finding also supports our ear-
lier conclusion that JunB does not act through the Akt/mTOR 
signaling pathway (Figs. 3, B–D and S3 C), whose activation 
suppresses basal protein degradation (Sacheck et al., 2007).
JunB interacts with FoxO3 and inhibits  
its binding to the atrogin-1 promoter
To clarify the mechanism by which JunB reduces the induction   
of atrogin-1 and MuRF-1, the stimulation of proteolysis by   
ca-FoxO3, and the loss of muscle mass, we tested by ChIP the 
ability of JunB to inhibit FoxO3 binding to the atrogin-1 pro-
moter in myotubes infected either with JunB or JunB together 
with ca-FoxO3 adenoviruses. As predicted, JunB overproduc-
tion in C2C12 myotubes strongly reduced the binding of FoxO3 
to its specific recognition sequences on the promoter (Fig. 6 A, 
left). In the same myotubes, we also tested the ability of JunB to 
interact with specific AP-1 binding sequences on the atrogin-1 
promoter, and indeed we confirmed that this factor binds to the 
promoter of this crucial ubiquitin ligase (Fig. 6 A, right).
Interestingly, one of the AP-1 binding sites in the atrogin-1 
promoter lies close to the FoxO binding site (Fig. 6 A), and it 
seemed likely that JunB might interact with this AP-1 site and 
thereby might inhibit the binding of FoxO3 to this promoter.   
To examine this possibility, we cloned this promoter region up-
stream of the luciferase gene and then mutagenized the AP-1 
site. FoxO3 was able to induce the two reporters, the wild type and 
the mutated one (Fig. 6 B), and, surprisingly, JunB coexpression 
was still able to block FoxO3’s action on both promoters (Fig. 6 B). 
Furthermore, this inhibition of both promoters by JunB did not 
require the presence of its DNA-binding domain (Fig. 6 B). 
Thus, this important ability of JunB to inhibit FoxO activity 
does not require JunB binding to the atrogin-1 promoter. FoxO 
activity is regulated not only by multiple posttranslational mod-
ifications (including acetylation, ubiquitination, and phosphory-
lation) but also by interactions with other proteins (Calnan and 
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JunB overexpression leads to dramatic hypertrophy of both 
myotubes (Fig. 4, D and F) and adult mouse muscles (Fig. 2)   
by stimulating overall protein synthesis (Fig. 3 A) and myo-
sin expression (Fig. 3, E and F), and, surprisingly, JunB does 
so without activating the mTOR/S6K pathway (Fig. 3, B–D) 
and without reducing basal protein degradation (Fig. 5 E). We 
have recently shown that inhibition of the TGF- pathway also   
Thus, it is likely that the fall in JunB expression (Lecker et al., 2004; 
Sacheck et al., 2007) and its exclusion from the nucleus in atrophy-
ing muscles (Fig. 1 A) contribute to the loss of muscle protein in   
various catabolic conditions. In particular, based on JunB’s ability   
to stimulate muscle protein synthesis and myosin expression, 
their fall in catabolic (i.e., JunB deficient) states is likely to be 
caused, at least in part, by the reduced JunB activity.
Figure 6.  JunB interacts with FoxO3, prevents its binding to the atrogin-1 promoter, and inhibits the activity of the myostatin/Smad pathway. (A) JunB 
inhibits the recruitment of FoxO3 to the atrogin-1 promoter. Differentiated myotubes were infected with either mock (GFP), JunB, ca-FoxO3, or ca-FoxO3 
and JunB adenoviruses. 48 h later, ChIP was performed using an anti-FoxO3, an anti-JunB, and anti-acetyl histone–specific antibodies. A set of primers that 
cover the JunB and FoxO3 response elements of the atrogin-1 promoter were used to amplify by PCR the related DNA fragments on the atrogin-1 promoter 
as depicted in the top panel. (B) FoxO3 recruitment on the atrogin-1 promoter is blocked by JunB independently of the AP-1 binding site. A plasmid coding   
for the region of the atrogin-1 promoter (155 bp) containing the FoxO and AP-1 sites (or the mutated one) linked to a minimal SV40 promoter and a 
luciferase reporter was transfected into adult TA muscles in the presence or absence of ca-FoxO3, wild-type JunB (JunB), or a JunB mutant lacking the 
DNA-binding domain (JunB DBD) with the renilla luciferase construct (pRL-TK) to normalize for transfection efficiency. 6 d later, firefly/renilla luciferase 
activity was determined. n = 4; means ± SD. (C) JunB interacts with FoxO3. (top) Differentiated myotubes were infected with adenoviruses expressing either 
mock (GFP), JunB, or JunB and ca-FoxO3. 2 d later, HA-tagged FoxO3 was immunoprecipitated from cell proteins with a specific anti-HA antibody. The 
immunoprecipitated proteins were immunoblotted with anti-HA and JunB antibodies. (bottom) Endogenous JunB was immunoprecipitated from C2C12 myo-
tubes using the anti-JunB–specific antibody. The eluted proteins were assayed by immunoblotting and visualized with anti-FoxO3 and anti-JunB antibodies.   
(D) JunB inhibits myostatin expression in differentiated myotubes. C2C12 myotubes were infected with either mock (GFP) or JunB adenoviruses for 12, 24, 
36, and 48 h. Myostatin expression was assessed by quantitative RT-PCR. (B and D) *, P < 0.001. (E) Myostatin treatment does not influence JunB expression 
in differentiated myotubes. Adult myotubes were treated with either 10 or 100 µg/ml myostatin for 2 d and analyzed by quantitative RT-PCR. (D and E) n = 3;   
means ± SD. (F) JunB inhibits Smad3 phosphorylation in myotubes. Differentiated myotubes were infected with mock (GFP)-, JunB-, and ca-FoxO3–specific 
adenoviruses. 24 h later, the cells were collected, and proteins were immunoblotted with specific antibodies for phospho-Smad3 and total Smad2/3.JCB • VOLUME 191 • NUMBER 1 • 2010   110
differentiation medium and treated with 100 µM dexamethasone (Sigma-
Aldrich) or with PBS for 5 h with 10 or 100 µg/ml myostatin (R&D Systems) 
as previously described (Trendelenburg et al., 2009) and with 200 nM 
bafilomycin A (LC Laboratories) for 5 h as previously described (Romanello 
et al., 2010). Experiments were performed on an inverted microscope 
(IX81; Olympus) with the UPlan FLN 20×/0.5 NA objective (Olympus). 
The microscope was equipped with a charge-coupled device camera (SIS 
F-View; Olympus), an illumination system (MT20; Olympus), and a beam-
splitter optical device (Multispec Microimager; Optical Insights). Images 
were collected using Cell-R software (Olympus). The cells were fixed with 
4% PFA for 10 min and maintained in PBS solution at room temperature. 
Myotube diameter was measured in 1,000 myotubes for each condition 
using IMAGE software (Scion Corporation). All the data are expressed 
as means ± SEM. Comparisons were made using the Student’s t test with   
P < 0.05 being considered statistically significant.
The infection efficiency was typically >90%. Adenoviruses express-
ing ca-FoxO3 and GFP were described previously in Skurk et al. (2004).
Adenovirus production
The adenovirus expressing JunB was created using the AdEasy strategy 
(Agilent Technologies). Human JunB cDNA was cloned in the pAdTrack cyto-
megalovirus vector (Agilent Technologies). Subsequent steps were performed 
according to the manufacturer’s instructions. Adenoviral vectors contain 
two distinct promoters that independently drive the expression of the gene 
of interest and of GFP. Therefore, mock plasmid expresses only GFP.
Plasmids
The expression plasmid for wild-type JunB was provided by J.S. Brugge 
(Harvard Medical School, Boston, MA). The JunB mutant lacking the DNA-
binding domain was created by the deletion of 21 amino acids (amino acids 
249–270) by mutagenesis PCR using the wild-type JunB expression vector as 
a template and the mutagenesis primer 5-CAGACCGTGCCGGAGGC-
GGTGGAGCGCAAGCGGCTG-3. The expression vector coding for c-Jun 
was provided by J. Blenis (Harvard Medical School, Boston, MA).
The reporter construct containing 155 bp of the atrogin-1 promoter 
(from 3,088 to 2,933) driving the firefly luciferase gene was created by 
PCR with the oligonucleotide primers used also for the ChIP experiments and 
inserted into the KpnI and XhoI sites of pGL3-Promoter Vector (Promega). The 
oligonucleotide primers used for the PCR reaction are forward 5-TCCCTG-
CAGGATGAAATGTT-3 and reverse 5-GTATGCCCTGGGTCCAAGT-3.
Mutations in the AP-1 binding site were generated by PCR using 
the QuickChange technique (Agilent Technologies). The oligos (AP-1 site 
is in bold and the mutated nucleotides are underlined) used are atrogin-1 
wild  type  (5-CAAACAAGATTTTGCCAATTTCCTGAGTCAAATTTGGAGA-
CGGCTTTGCC-3)  and  atrogin-1  mutated  (5-CAAACAAGATTTTGC-
CAATTTCCTGCCGCAAATTTGGAGACGGCTTTGCC-3).
Transient transfection and luciferase assays in muscle cell cultures
Myoblasts were transfected with different reporters using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions. Generally, 
100 × 10
3 C2C12 cells were seeded into individual wells of 12-well plates 
24 h before transfection with either 3.5 kb of atrogin-1 promoter (3.5 AT1)   
or 5 kb of MuRF-1 promoter (5.0 MuRF-1) reporter constructs and pRL-TK 
(Promega) with or without either JunB or ca-FoxO3 expression vectors (2 µg   
of total DNA/well, 0.5 µg of reporter, 0.5 µg pRL-TK, 1 µg JunB expression 
vector, and 1 µg ca-FoxO3 expression vector). When the cells reached 
confluence, the medium was shifted to differentiation medium to induce 
myotube formation. After 5 d, myotubes were treated either with 10 µM 
dexamethasone for 24 h or with PBS for 5 h. After these treatments, myo-
tubes were lysed and analyzed using the Dual-Luciferase Reporter Assay 
System (Promega) according to the manufacturer’s instructions. To control 
for transfection efficiency, firefly luciferase activity was divided by renilla 
luciferase  activity.  Luciferase  measurements  in  muscles  transfected  with 
reporter  constructs  were  performed  similarly,  except  that  the  harvested 
muscles were quick frozen and powdered in liquid nitrogen before the 
addition of the lysis buffer (Serrano et al., 2001). Results are expressed as 
means ± SD of at least three independent experiments.
Adult mouse skeletal muscle transfection and treatments
Adult male CD1 mice (2 mo of age) were used in all overexpression experi-
ments. In the RNAi experiments, adult male CD1 mice (3 mo of age) were 
used. TA muscles were transfected as described previously (Donà et al., 
2003). The muscle was isolated through a small hindlimb incision, and 20 µg   
of plasmid DNA was injected along the muscle length. In the reporter experi-
ments, 20 µg of the expression vector with 10 µg of either 2.8 MyHC-2B, 
promotes  muscle  growth  by  an Akt-independent  mechanism 
(Sartori et al., 2009). Indeed, JunB blocks myostatin expres-
sion and thus inhibits the TGF-/Smad pathway. How much 
of JunB’s growth-promoting effect is mediated via myostatin 
inhibition is an interesting point that merits more detailed inves-
tigations. Alternatively, JunB and decreased myostatin activity 
may enhance protein synthesis via related mTOR-independent   
mechanisms, such as increasing translational efficiency or ribo-
some content. Importantly, the prevention of denervation atrophy 
by JunB (Fig. 4, A–C) cannot be ascribed solely to the inhibition 
of FoxO3 activity because its overexpression did not completely 
abolish FoxO3-mediated protein breakdown (Fig. 5 E). There-
fore, other JunB actions (e.g., its stimulation of protein synthe-
sis) must be crucial in inducing such rapid growth of normal 
muscle, whereas JunB’s ability to prevent fiber atrophy upon 
denervation (Fig. 4, A–C) must reflect a combination of differ-
ent actions, including the enhancement of synthesis (Fig. 3 A) 
together with JunB’s interaction with FoxO to inhibit the activa-
tion of proteolysis (Fig. 5 E).
Although Akt activation and JunB expression can both pre-
vent FoxO3 binding to the promoters of atrogin-1 and MuRF-1   
and the induction of these (and presumably certain other) atro-
genes, Akt and JunB do so by very different mechanisms and to 
different extents. Akt phosphorylates FoxO3 and thereby pre-
vents its migration to the nucleus (Sandri et al., 2004). In con-
trast, JunB associates with FoxO3 (Fig. 6 C) and thus reduces   
FoxO3 recruitment to promoters of key atrogenes (Fig. 6, A and B).   
Akt and JunB also seem to have distinct effects on protein   
degradation. When activated, Akt causes a general reduction in 
protein degradation in normal and atrophying muscles and myo-
tubes (Zhao et al., 2007) by suppressing autophagy through mTOR 
stimulation and by inactivating FoxO3, which prevents the ac-
tivation of both the autophagic/lysosomal and the ubiquitin– 
proteasomal pathways. In contrast, JunB lowers only the acceler-
ated proteolysis induced by activated FoxO3 but does not block 
the activation of autophagy by FoxO3 (Fig. 5, F–I). Because 
JunB overexpression can prevent completely the loss of mus-
cle mass upon denervation (Fig. 4, A–C), JunB, by binding to 
FoxO3, appears to reduce its capacity to cause atrophy-related 
gene induction and probably also stimulates protein synthesis.
Presently, no therapies are available to combat the debilitat-
ing loss of muscle in bed-ridden patients during acute systemic 
diseases (e.g., cancer, sepsis, or neurodegenerative disease) or 
in the frail elderly. Because increasing JunB can cause marked 
hypertrophy and can block the rapid loss of muscle mass upon 
denervation or by FoxO3 activation, raising or maintaining JunB 
levels represents a potential new therapeutic target for the devel-
opment of drugs that ameliorate the muscle wasting that accom-
panies many systemic diseases.
Materials and methods
Cell culture, adenoviral infection, and measurement of myotube diameter
C2C12 myoblasts (American Type Culture Collection) were cultured in 
DME + 10% FBS (Invitrogen) until cells reached confluence. The medium 
was then replaced with DME + 2% horse serum (Invitrogen) and incubated 
for 5 d before proceeding with experiments. For infection, 5-d differen-
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Protein synthesis measurement in C2C12 myotubes
Total protein synthesis was measured by monitoring the incorporation of 
[
3H]tyrosine into cell proteins according to the procedure of White et al. 
(1988). C2C12 myotubes were infected with GFP or JunB adenoviruses for 
12, 24, 36, and 48 h, and, where indicated, the cells were treated for 12 
and 36 h with 20 ng/ml rapamycin (LC Laboratories). Cells were then ex-
posed to 5 µCi/ml [
3H]tyrosine for 2 h. At the completion of the incubation 
period, the media were discarded. The wells were washed twice with PBS, 
and 1 ml of 10% TCA was added to each well to precipitate the proteins and 
incubated for 30 min at 4°C. Cells were removed from the plates using a rub-
ber scraper and transferred to microfuge tubes. Tubes were spun for 5 min at 
12,000 g at 4°C. The resulting pellet was washed with 1 ml of 95% ethanol. 
The pellet was solubilized in 1 ml of 0.1-M NaOH at 24°C for 2-h rocking. 
These samples were analyzed for both radioactivity and protein. For radio-
activity measurements, 100 µl of each sample was transferred to a scintillation 
vial (Research Products International) with 3-ml scintillation cocktail (Ecolite; 
ICN Biomedicals, Inc.). Samples were mixed thoroughly and counted in a   
liquid scintillation counter (Packard Instruments). Total protein concentration 
was determined testing 50 µl of cellular material with the Bradford method 
(Thermo Fisher Scientific). Results were expressed as disintegrations per minute 
per milligram of protein for each well normalized on the control. Results are 
expressed as means ± SD of six independent experiments.
In vivo RNAi
In vivo RNAi experiments were performed as described previously (Sandri 
et al., 2004) using JunB siRNA (Invitrogen) to specifically knock down JunB. 
As a control, a nontargeting siRNA (scramble) was used (Invitrogen). The 
constructs are bicistronic vectors that encode shRNAs and GFP. Therefore, 
transfected fibers coexpress GFP together with the oligos. For the validation 
of siRNA constructs, murine embryonic fibroblasts were maintained in DME + 
10% FBS (Invitrogen) and transfected with siRNA constructs using Lipo-
fectamine 2000. Cells were lysed 72 h later, and proteins were purified 
and subjected to immunoblotting with specific antibodies against JunB.
Protein extraction and Western blotting
Total proteins were extracted by solubilization in lysis buffer (50 mM Tris,   
pH 7.5, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT, 1 mM EDTA, 10% glyc-
erol, 2% SDS, 1% Triton X-100, 1 mM PMSF, 1 mM NaV, 5 mM NaF, 3 mM 
-glycerol, and Complete EDTA-free protease inhibitor mixture [Roche]). Cyto-
plasmatic fraction from C2C12-differentiated myotubes was obtained with   
10 mM Hepes, pH 7.6, 60 mM KCl, 1 mM EDTA, pH 8, and 0.1% NONIDET   
P-40. Nuclei were lysed with 20 mM Tris, pH 7.6, 420 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, and 25% glycerol.
Protein  concentration  was  quantified  using  the  Bradford  method.   
30 µg of the whole-cell lysates and either the cytoplasmic or nuclear fraction 
was loaded and separated on 4–12% precast gels (Bis–Tris NuPAGE; Invitro-
gen). Proteins were transferred to Hybond-C Extra membrane (GE Healthcare) 
and stained with Ponceau S solution (Sigma-Aldrich) to verify the efficiency of 
the transfer. The blots were incubated in blocking buffer (TBS, 0.1% Tween 
20, and 5% nonfat milk) for 1 h at room temperature. Membranes were 
washed in washing buffer (TBS and 0.1% Tween 20) three times for 5 min 
each, probed with the primary antibody in TBS, 0.1% Tween 20, and 2% 
nonfat milk overnight at 4°C, and then probed with the secondary antibody 
for 1 h in TBS, 0.1% Tween 20, and 2% nonfat milk. The antibody reaction 
was analyzed using the ECL method (Thermo Fisher Scientific).
The following antibodies from Cell Signaling Technology were used: 
anti-Akt, anti–phospho-Akt (Ser473), anti–phospho-FKHRL1 (Ser253), anti-
4EBP1, anti–phospho-4EBP1 (Ser65), anti–phospho-4EBP1 (Thr 37/46),   
anti-p70 S6 kinase, anti–phospho-p70 S6 kinase (Thr389), anti-S6, anti– 
phospho-S6 (Ser240/244), mTOR, and anti–phospho-Smad3 (Ser423/425). 
The following antibodies from Abcam were used: anti-JunB, anti-Raptor, 
anti-Fos, and anti-Fra1. The following antibodies from Santa Cruz Bio-
technology, Inc. were used: anti-FKHRL1, anti–-tubulin, anti-GFP, anti-HDAC1, 
and anti-HA. The antibody anti-Smad2/3 was purchased from BD, the   
LC3 antibody was obtained from NanoTools, and the p62 antibody was 
purchased from PROGEN.
RNA extraction and gene expression analyses
Total RNA was purified from C2C12 myotubes infected either with GFP or 
JunB at different time points or from muscles transfected with scramble and 
JunB RNAi constructs for 12 d after the standard TRIZOL protocol (Invitro-
gen). The RNA was quantified and controlled for its quality using the RNA 
6000  LabChip  kit  (Agilent  Technologies)  in  conjunction  with  a  2100   
Bioanalyzer (Agilent Technologies). Complementary DNA generated with 
a cDNA synthesis kit (SuperScript VILO; Invitrogen) was analyzed by 
quantitative real-time RT-PCR using the SYBR green chemistry (Finnzymes). 
3.5 AT1 or 5.0 MuRF-1 or 155 bp atrogin-1 promoter reporter constructs 
and 5 µg pRL-TK vectors were coinjected. Electric pulses were then ap-
plied by two stainless steel spatula electrodes placed on each side of the 
isolated muscle belly (21 V/cm for five pulses at 200-ms intervals). For the 
determination of the number of autophagic vesicles, mouse TA muscles of 
2-mo-old mice were electroporated with YFP-LC3 expression plasmid and 
starved for 24 h as previously described (Mammucari et al., 2007). JunB   
overexpression experiments were performed on 2-mo-old mice. Electro-
porated muscles were collected 6, 9, or 12 d later. No gross or microscopic 
evidence for necrosis or inflammation as a result of the transfection proce-
dure was noted. For the BrdU experiments, CD1 mice were electroporated 
with the JunB expression vector. BrdU was injected every day starting from 
day 5 after transfection until the animal was sacrificed. Every injection 
contained 50 mg/kg BrdU dissolved in 100 µl of 0.9% NaCl. Satellite 
cell activation and muscle regeneration were induced by injection in TA 
muscles of 10 µl of 35-µM cardiotoxin (Sigma-Aldrich). For the inhibition 
of protein synthesis, in vivo CD1 mice were injected subcutaneously every 
day for 5 d with 15 mg/kg cycloheximide (Sigma-Aldrich) dissolved in 
0.9% NaCl as previously described (Fan et al., 2010).
Immunohistochemistry, fiber size measurements, and determination  
of the number of autophagic vesicles
10-µm-thick cryosections of muscles overexpressing either JunB or c-Jun for 
9 d were fixed by 4% paraformaldehyde. Immunohistochemistry with   
either an anti-JunB polyclonal antibody (Santa Cruz Biotechnology, Inc.) or 
an anti–c-Jun polyclonal antibody (Abcam) was performed as previously 
described (Sandri et al., 2004; Mammucari et al., 2007; Sartori et al., 
2009). Muscle fiber size was measured in fibers expressing JunB or c-Jun 
and in equal numbers of untransfected fibers from the same muscle as pre-
viously described (Mammucari et al., 2007; Sartori et al., 2009). Cryo–
cross  sections  were  also  stained  with  antidystrophin-specific  antibodies 
(Sigma-Aldrich and Abcam).
Inducible muscle-specific Akt transgenic mice are described in   
Mammucari et al. (2007). Transgenic animals were electroporated with 
the  JunB  expression  vector  and,  immediately  after  the  electroporation, 
were injected with 1.5 µg tamoxifen (Sigma-Aldrich) to induce the expres-
sion of Akt (Mammucari et al., 2007). The treatment was repeated every 
other day to maintain Akt expression for the duration of the experiment. 
Control animals received only oil vehicle. After 9 d from the electropora-
tion of JunB, the muscles were collected, and transfected fibers were re-
vealed  by  immunohistochemistry  with  specific  antibodies  against  JunB. 
Cross-sectional area was measured in fibers overexpressing JunB and com-
pared with an equal number of surrounding untransfected fibers.
For the determination of the number of autophagic vesicles, cryosec-
tions of muscle transfected with YFP-LC3 expression plasmid were exam-
ined using a fluorescence microscope, and fluorescent dots were counted 
as described previously, normalizing for cross-sectional area (Mizushima 
et al., 2004; Mammucari et al., 2007).
To identify BrdU-positive nuclei, 4–6-µm cryostat sections were in-
cubated with 4 M HCl and trypsin to expose the DNA to the antibody 
as  previously  described  (Sartori  et  al.,  2009).  The  antibody  against 
BrdU-FITC conjugate was purchased from Abcam, and the antibody anti-
laminin was obtained from Sigma-Aldrich. All fiber cross-sectional areas 
were measured using IMAGE software. Slides were mounted with Elvanol 
(Sigma-Aldrich)  and  analyzed  with  a  microscope  (DM5000B;  Leica)   
using an HCPL Fluotar 20×/0.5 NA objective lens (Leica). Images were 
collected with a camera (DFC300FX; Leica) and analyzed with IM50 
Image software (Leica).
All the data are expressed as means ± SEM. Comparisons were 
made using the Student’s t test with P < 0.05 being considered statisti-
cally significant.
Protein degradation measurement in C2C12 myotubes
C2C12 myotubes were incubated with 5 µCi/ml [
3H]tyrosine for 20 h to 
label cell proteins and then were switched to chase medium (containing   
2 mM of unlabeled tyrosine to prevent reincorporation of [
3H]tyrosine; 
Gronostajski et al., 1984) for 2 h. Fresh chase medium containing GFP, 
JunB,  ca-FoxO3,  or  JunB  together  with  ca-FoxO3  adenoviruses  was 
added, and media samples were collected over 32 h and combined with 
TCA (10% final concentration) to precipitate proteins. The acid-soluble 
radioactivity reflects the amount of prelabeled, long-lived proteins de-
graded at different times and was expressed relative to the total radio-
activity initially incorporated. Plotting these values versus time gave the 
total rate of proteolysis. Results are expressed as means ± SD of six 
independent experiments.JCB • VOLUME 191 • NUMBER 1 • 2010   112
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Coimmunoprecipitation
C2C12 myotubes at the fourth day of differentiation were infected with 
either GFP, JunB, or JunB together with ca-FoxO3 adenoviruses. The cells 
were collected 2 d after the infection, and total proteins were extracted in 
an appropriate volume of lysis buffer (150 mM NaCl, 1% Triton X-100,   
50 mM Tris-HCl, pH 7.5, and Complete EDTA-free protease inhibitor mix-
ture). The coimmunoprecipitation was performed with the ProFound HA Tag 
IP/Co-IP kit (Thermo Fisher Scientific) because ca-FoxO3 is HA tagged. The 
eluted proteins were separated by SDS-PAGE gel electrophoresis, trans-
ferred to Hybond-C Extra membrane, and stained with Ponceau S solution. 
ca-FoxO3 was visualized with polyclonal anti-HA antibody (Santa Cruz 
Biotechnology, Inc.), and JunB was visualized with polyclonal anti-JunB   
antibody (Abcam). The immunoprecipitation of JunB to detect the inter-
action with Fos and Fra1 and the immunoprecipitation of endogenous JunB 
from C2C12 myotubes at the sixth day of differentiation were performed 
using the Direct IP kit (Thermo Fisher Scientific).
ChIP assays and promoter analyses
C2C12 myotubes at the fourth day of differentiation were infected with 
either mock (GFP), ca-FoxO3, JunB, or JunB with ca-FoxO3 adenoviruses. 
2 d after infection, ChIP was performed with ChIP assay kit (Millipore)   
according to the manufacturer’s instructions.
Oligonucleotide primers for amplification of a FoxO binding site on   
the atrogin-1 promoter are forward 3,228 bp (5-CTGGCAGGGAGG-
AGCCTAATGAATC-3) and reverse 2,966 bp (5-GGGAGTGGCAAAG-
CCGTCTC-3). Oligonucleotide primers for amplification of a JunB site on   
the atrogin-1 promoter are forward 3,088 bp (5-TCCCTGCAGGATGA-
AATGTT-3) and reverse 2,933 bp (5-GTATGCCCTGGGTCCAAGT-3). 
Oligonucleotide primers for the amplification of a JunB site on the MyHC-2B 
promoter are forward 1,384 bp (5-GAGGTCGGTAGTCAGTCTCTTTT-3) 
and reverse 1,199 bp (5-TACCCCAAGTGTTAGGCTCA-3).
Online supplemental material
Fig.  S1  shows  images  of  cryosections  of  muscles  electroporated  with 
JunB shRNA. Fig. S2 shows images of cryosections of muscles treated 
with BrdU and quantification of myofiber size after cycloheximide treat-
ment. Fig. S3 shows the efficiency of siRNA-mediated knockdown of JunB.   
Fig. S4 shows the level of overexpression of JunB and ca-Fox03 in myo-
tubes by transient transfection and by adenoviral infection, the results of 
the immunoprecipitation of JunB and the interaction with Fos and Fra1. 
Fig. S5 is a bar diagram showing the mRNA expression mediated by 
JunB on the mRNAs of atrogin-1, MuRF-1, and on some of the autophagy-
related genes. Online supplemental material is available at http://www 
.jcb.org/cgi/content/full/jcb.201001136/DC1.
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